Circulating Interferon-Inducible Protein IFI16 Correlates with Clinical and Serological Features in Rheumatoid Arthritis

Arthritis Care and Research

Volumn 68, Issue 4, 2016, Pages 440-445

  Alunno, Alessia ^a   Caneparo, Valeria ^b   Bistoni, Onelia ^a   Caterbi, Sara ^a   Terenzi, Riccardo ^a   Gariglio, Marisa ^b   Bartoloni, Elena ^a   Manzo, Antonio ^c   Landolfo, Santo ^d   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Virology Unit Department of Translational Medicine Novara Medical School   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IFI16 ANTIBODY; INTERFERON INDUCIBLE PROTEIN IFI16; PROTEIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IFI16 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; IMMUNOPATHOGENESIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEROLOGY; SMOKING; SYNOVIAL FLUID; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; COMPLICATION; IMMUNOLOGY; LUNG DISEASES; OSTEOARTHRITIS; UPREGULATION;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OSTEOARTHRITIS; PEPTIDES, CYCLIC; PHOSPHOPROTEINS; RHEUMATOID FACTOR; SEROLOGIC TESTS; SYNOVIAL FLUID; UP-REGULATION;

EID: 84961959015     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22695     Document Type: Article

References (24)

1. Ronnblom L, Eloranta ML., The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013; 25: 248-53.
2. Crow MK., Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192: 5459-68.
3. Nguyen CQ, Peck AB., The interferon-signature of Sjögren's syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol 2013; 4: 142.
4. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al., Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029-36.
5. Sozzani S, Bosisio D, Scarsi M, Tincani A., Type I interferons in systemic autoimmunity. Autoimmunity 2010; 43: 196-203.
6. Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, et al., The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis 2013; 72: 776-80.
7. Wright HL, Thomas HB, Moots RJ, Edwards SW., Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (Oxford) 2015; 54: 188-93.
8. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al., The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
9. Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, et al., Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol 2014; 66: 1421-31.
10. Bawadekar M, De Andrea M, Gariglio M, Landolfo S., Mislocalization of the interferon inducible protein IFI16 by environmental insults: implications in autoimmunity. Cytokine Growth Factor Rev 2015; 26: 213-9.
11. Gugliesi F, De Andrea M, Mondini M, Cappello P, Giovarelli M, Shoenfeld Y, et al., The proapoptotic activity of the interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. J Autoimmun 2010; 35: 114-23.
12. Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo P, D'Ambrosio R, et al., A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 2006; 54: 3939-44.
13. Caneparo V, Cena T, De Andrea M, Dell'Oste V, Stratta P, Quaglia M, et al., Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Lupus 2013; 22: 607-13.
14. Costa S, Mondini M, Caneparo V, Afeltra A, Airo P, Bellisai F, et al., Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. Rheumatology (Oxford) 2011; 50: 674-81.
15. Costa S, Borgogna C, Mondini M, De Andrea M, Meroni PL, Berti E, et al., Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. Br J Dermatol 2011; 164: 282-90.
16. Gugliesi F, Bawadekar M, De Andrea M, Dell'Oste V, Caneparo V, Tincani A, et al., Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding. PLoS One 2013; 8: e63045.
17. Uchida K, Akita Y, Matsuo K, Fujiwara S, Nakagawa A, Kazaoka Y, et al., Identification of specific autoantigens in Sjögren's syndrome by SEREX. Immunology 2005; 116: 53-63.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
19. Dell'Oste V, Gatti D, Gugliesi F, De Andrea M, Bawadekar M, Lo Cigno I, et al., Innate nuclear sensor IFI16 translocates into the cytoplasm during the early stage of in vitro human cytomegalovirus infection and is entrapped in the egressing virions during the late stage. J Virol 2014; 88: 6970-82.
20. Catrina AI, Ytterberg AJ, Reynisdottir G, Malmstrom V, Klareskog L., Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10: 645-53.
21. Zhu J, Zhou Y, Chen X, Li J., A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol 2014; 41: 1282-9.
22. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al., Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics - A large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676-82.
23. Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D., The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford) 2014; 53: 1940-50.
24. Arend WP, Firestein GS., Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012; 8: 573-86.